114 related articles for article (PubMed ID: 23769056)
21. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
22. Reactivity of hybridomas derived from T cells activated in vivo during graft-versus-host disease.
Leibnitz RR; Lipsky PE; Thiele DL
J Immunol; 1994 Dec; 153(11):4959-68. PubMed ID: 7963559
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulation with donor regulatory T cells armed with Fas-ligand alleviates graft-versus-host disease.
Yolcu ES; Kaminitz A; Mizrahi K; Ash S; Yaniv I; Stein J; Shirwan H; Askenasy N
Exp Hematol; 2013 Oct; 41(10):903-11. PubMed ID: 23743300
[TBL] [Abstract][Full Text] [Related]
24. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
25. Induction of acute graft-versus-host disease by T cells that do not respond to in vitro alloantigen stimulation.
New JY; Chan SH; Yap EH; Hu H
Br J Haematol; 2004 Sep; 126(6):828-36. PubMed ID: 15352987
[TBL] [Abstract][Full Text] [Related]
26. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
[TBL] [Abstract][Full Text] [Related]
27. Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation.
Pachnio A; Dietrich S; Klapper W; Humpe A; Schwake M; Sedlacek R; Gramatzki M; Beck C
Bone Marrow Transplant; 2006 Jul; 38(2):157-67. PubMed ID: 16820783
[TBL] [Abstract][Full Text] [Related]
28. Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection.
Askenasy N; Yolcu ES; Wang Z; Shirwan H
Circulation; 2003 Mar; 107(11):1525-31. PubMed ID: 12654611
[TBL] [Abstract][Full Text] [Related]
29. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.
Giorgini A; Noble A
J Leukoc Biol; 2007 Nov; 82(5):1053-61. PubMed ID: 17684039
[TBL] [Abstract][Full Text] [Related]
30. Lymphopenia-induced proliferation of donor T cells reduces their capacity for causing acute graft-versus-host disease.
Maeda Y; Tawara I; Teshima T; Liu C; Hashimoto D; Matsuoka K; Tanimoto M; Reddy P
Exp Hematol; 2007 Feb; 35(2):274-86. PubMed ID: 17258076
[TBL] [Abstract][Full Text] [Related]
31. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect.
Imado T; Iwasaki T; Kuroiwa T; Sano H; Hara H
Transplantation; 2004 Feb; 77(3):391-8. PubMed ID: 14966413
[TBL] [Abstract][Full Text] [Related]
32. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
33. Localized immune tolerance from FasL-functionalized PLG scaffolds.
Skoumal M; Woodward KB; Zhao H; Wang F; Yolcu ES; Pearson RM; Hughes KR; García AJ; Shea LD; Shirwan H
Biomaterials; 2019 Feb; 192():271-281. PubMed ID: 30458362
[TBL] [Abstract][Full Text] [Related]
34. Immunomodulation with SA-FasL protein as an effective means of preventing islet allograft rejection in chemically diabetic NOD mice.
Yolcu ES; Zhao H; Shirwan H
Transplant Proc; 2013 Jun; 45(5):1889-91. PubMed ID: 23769064
[TBL] [Abstract][Full Text] [Related]
35. Graft-versus-host-disease-associated donor cell engraftment in an F1 hybrid model is dependent upon the Fas pathway.
Iwasaki T; Hamano T; Saheki K; Kuroiwa T; Kataoka Y; Takemoto Y; Ogata A; Fujimoto J; Kakishita E
Immunology; 2000 Jan; 99(1):94-100. PubMed ID: 10651946
[TBL] [Abstract][Full Text] [Related]
36. Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.
Chen C; Cao J; Zeng L; Li Y; Wang D; Xu K
Transplant Proc; 2011 Jun; 43(5):2041-8. PubMed ID: 21693322
[TBL] [Abstract][Full Text] [Related]
37. Effects of T cell depletion in radiation bone marrow chimeras. III. Characterization of allogeneic bone marrow cell populations that increase allogeneic chimerism independently of graft-vs-host disease in mixed marrow recipients.
Sykes M; Chester CH; Sundt TM; Romick ML; Hoyles KA; Sachs DH
J Immunol; 1989 Dec; 143(11):3503-11. PubMed ID: 2584703
[TBL] [Abstract][Full Text] [Related]
38. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
39. ProtEx: a novel technology to display exogenous proteins on the cell surface for immunomodulation.
Singh NP; Yolcu ES; Askenasy N; Shirwan H
Ann N Y Acad Sci; 2005 Nov; 1056():344-58. PubMed ID: 16387700
[TBL] [Abstract][Full Text] [Related]
40. Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein.
Yolcu ES; Gu X; Lacelle C; Zhao H; Bandura-Morgan L; Askenasy N; Shirwan H
J Immunol; 2008 Jul; 181(2):931-9. PubMed ID: 18606644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
